Revenue for the quarter ended December 31, 2025, is $398.3 million, up 34.9% sequentially and 15.9% year-over-yearNet income for the quarter ended December 31, 2025, is $7.8 millionAdjusted net income ...
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results